In patients presenting with acute coronary syndrome (ACS), higher plasmatic levels of PAPP-A were associated with an increased risk of major cardiovascular events at a two-year follow-up both in subjects with type-2 diabetes mellitus (T2DM) or without. Here, PAPPA is linked to type 2 diabetes mellitus.